BartBarlogieMD

Hematology • New York, NY

Director, Multiple Myeloma Research Program

Join to view full profile

Dr. Barlogie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barlogie's full profile

Already have an account?

Office
One Gustave L. Levy Place
Box 1185
New York, NY 10029
Phone+1 212-241-7873

Fax+1 212-241-8608

Education & Training

University of Heidelberg Faculty of MedicineClass of 1965

Certifications & Licensure

AR State Medical License 1989 - 2022
NY State Medical License 2016 - 2022
TX State Medical License 1976 - 2005

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Elected Member The American Society for Clinical Investigation, 1985
Join now to see all

Clinical Trials

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma Start of enrollment: 1994 Jan 01
Completed
Phase 3
UARK 2003-33, Total Therapy III Start of enrollment: 2004 Jan 01
Completed
Phase 2
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide Start of enrollment: 1998 Dec 01
Completed
Phase 2
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Start of enrollment: 1998 Aug 01
Completed
Phase 3
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma Start of enrollment: 1998 Feb 01
Completed
Phase 2
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Start of enrollment: 2004 Jan 01
Completed
Phase 3
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients Start of enrollment: 2002 Nov 01
Terminated
Phase 2
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy Start of enrollment: 2006 Nov 01
Active, not recruiting
Phase 3
Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01
Completed
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 Start of enrollment: 2006 Aug 01
Terminated
Phase 3
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma Start of enrollment: 2002 Aug 01
Completed
Phase 2
Preemptive Strike With Bortezomib in Multiple Myeloma Patients Start of enrollment: 2008 Feb 01
Terminated
Phase 3
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01
Active, not recruiting
Phase 3
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01
Active, not recruiting
Phase 2
UARK 2009-32 Compassionate Use Study of Carfilzomib Start of enrollment: 2009 Nov 01
No longer available
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Start of enrollment: 2013 Apr 01
Completed
Phase 2
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Start of enrollment: 2015 Mar 01
Withdrawn
Phase 2
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Start of enrollment: 2015 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

162 citations
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma
Leo Rasche, Edgardo J. Angtuaco, James E. McDonald, Amy Buros, Caleb K. Stein
Blood. 2017-07-06
372 citations
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla Bartel, Jeff Haessler, Tracy Brown, John D. Shaughnessy, Frits van Rhee
Blood. 2009-09-03
256 citations
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
Leo Rasche, Shweta S. Chavan, Owen W. Stephens, Purvi Patel, Ruslana Tytarenko
Nature Communications. 2017-08-16

Journal Articles

Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small Adipocytes
Bart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology

Abstracts/Posters

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Mutational Landscape of Primary Plasma Cell Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

MCRT Webcast: Immunotherapy - St. Louis MCRT Part 1February 11th, 2022
Minimal Residual Disease Negativity by Next-Generation Flow Cytometry Is Associated with Improved Organ Response in AL AmyloidosisFebruary 16th, 2021
Introduction the Combination of Bortezomib, Lenalidomide, AndMay 11th, 2020
Join now to see all